Using a murine model of ICI therapy (anti-cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) blockade), Vetizou et al. found that enhanced anti-cancer immunotherapy relies on the presence of Bacteroides fragilis or Bacteroides thetaiotaomicron within the gut microbiome [30]. Here, CTLA4 is linked to cancer.